Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC trimmed its holdings in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) by 95.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 76,506 shares of the company’s stock after selling 1,802,447 shares during the period. Geode Capital Management LLC owned approximately 0.89% of Citius Pharmaceuticals worth $306,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of CTXR. Fisher Asset Management LLC acquired a new position in Citius Pharmaceuticals during the 4th quarter valued at about $51,000. IFP Advisors Inc boosted its holdings in shares of Citius Pharmaceuticals by 21.2% in the fourth quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock valued at $162,000 after acquiring an additional 7,083 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Citius Pharmaceuticals during the third quarter valued at approximately $50,000. 16.88% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Citius Pharmaceuticals in a research note on Tuesday, February 18th.

Citius Pharmaceuticals Trading Up 6.5 %

Shares of Citius Pharmaceuticals stock opened at $0.77 on Friday. Citius Pharmaceuticals, Inc. has a 52 week low of $0.68 and a 52 week high of $26.25. The company’s 50-day moving average price is $1.24 and its two-hundred day moving average price is $3.45.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its earnings results on Friday, February 14th. The company reported ($1.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.05). As a group, analysts expect that Citius Pharmaceuticals, Inc. will post -4.5 earnings per share for the current fiscal year.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.